The pharmaceutical landscape is currently seeing significant advancements across both clinical-stage therapeutics for neurodegenerative diseases and optimized over-the-counter formulations. Recent industry developments highlight a push toward disease-modifying treatments and a strategic adaptation to regulatory environments and patient safety protocols.

Clinical Milestones in Alzheimer’s Disease

Addressing a substantial unmet medical need, clinical-stage biotech company Risen Pharma has initiated a Phase 2 trial (NCT07579884) in China for RP902. This oral, small-molecule drug candidate is being developed to treat Mild Cognitive Impairment (MCI) associated with Alzheimer’s disease. The demographic data underscores the urgency of this research: the prevalence of Alzheimer’s among the Chinese population aged 65 and older has reached 6.0%, affecting approximately 1 in 17 individuals.

The multi-center, randomized, double-blind, and placebo-controlled trial is designed to evaluate the safety and efficacy of RP902 in the MCI patient population. The primary endpoint is the change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score. This pivotal study is being co-led by Professor Yi Tang of Xuanwu Hospital and Professor Yongjun Wang of Beijing Tiantan Hospital.

Risen Pharma is specifically targeting patients carrying the ApoE ε4 allele. These individuals generally experience an earlier onset and a more rapid trajectory of cognitive decline, yet current therapeutic options for this subgroup remain severely limited. Preclinical studies of RP902 demonstrated a significant suppression of neurotoxic amyloid-beta (Aβ) oligomers alongside notable improvements in cognitive function. Having already completed Phase 1 trials with a favorable safety and tolerability profile, RP902 is positioned as a potential first-in-class disease-modifying therapy. Its oral administration pathway offers a distinct clinical advantage by potentially improving patient compliance compared to existing treatment modalities.

In parallel diagnostic developments, the AI-driven diagnostics firm Noul was recently selected as the lead institution for a cross-ministerial global clinical project. Backed by a 2.2 billion KRW grant, the company is aggressively accelerating its pathway toward securing US FDA clearance.

OTC Market Shifts: Adapting to Patient Safety and Lifestyle

In the consumer healthcare sector, pharmaceutical companies are actively reformulating products to align with stricter safety regulations and clinical efficacy. Daewoong Pharmaceutical is a prime example, having recently overhauled its comprehensive cold medication, C-Cold Premium, in response to increased government scrutiny and enforcement regarding drug-impaired driving.

The product’s architecture explicitly separates daytime and nighttime dosages to optimize both symptom relief and patient safety. The daytime formulation completely excludes chlorpheniramine, a first-generation antihistamine well-known for inducing drowsiness, thereby mitigating cognitive impairment risks for drivers and individuals requiring high daytime alertness. The nighttime formulation incorporates diphenhydramine to alleviate symptoms while promoting the uninterrupted sleep necessary for recovery. Daewoong also streamlined the dosing regimen to a single tablet per administration, packaging it in a highly targeted 3.3-day supply for initial symptom management.

Concurrently, Dong-A Pharmaceutical continues to consolidate its dominance in the OTC dermatology market. Its hydroquinone-based hyperpigmentation treatment, Melatoning Cream, recently surpassed 3 million cumulative units sold just five years post-launch. The medication utilizes a dual-action mechanism that simultaneously suppresses melanin synthesis and bleaches excessively pigmented tissues.

According to IQVIA data, Dong-A has maintained a market share exceeding 70% in this active ingredient category since 2023, shifting over 1.3 million units last year alone. To capitalize on this clinical and commercial success, the company expanded its portfolio to include a high-capacity 50g tube designed for broader dermatological applications across the body, reinforcing the clinical importance of addressing the etiology of hyperpigmentation through pharmacy-exclusive treatments.